The Manila Times59m
Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
Linvoseltamab is an investigational BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on MM cells with CD3-expressing T cells to facilitate T-cell activation and ...
PharmaTimes1h
Libtayo available in Scotland for cervical cancer patients
Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...
CURE21h
THIO and Libtayo Extends OS in NSCLC Following Progression on SOC Therapy
THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...
Managed Healthcare Executive21h
AI Model Shows Promise in Reducing Skin Cancer Detection Bias
A novel AI model was able to achieve 99.86% accuracy for diagnosing skin conditions, even in people with darker skin tones or ...
PharmiWeb23h
Libtayo® (cemiplimab) Now Available on the National Health Service in Scotland for Patients with Recurrent or Metastatic Cervical Cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...